Efficacy of Roflumilast Foam, 0.3%, in Patients With Seborrheic Dermatitis: A Double-blind, Vehicle-Controlled Phase 2a Randomized Clinical Trial

IMPORTANCE: Current topical treatment options for seborrheic dermatitis are limited by efficacy and/or safety. OBJECTIVE: To assess safety and efficacy of roflumilast foam, 0.3%, in adult patients with seborrheic dermatitis affecting the scalp, face, and/or trunk. DESIGN, SETTING, AND PARTICIPANTS:...

Descripción completa

Detalles Bibliográficos
Autores principales: Zirwas, Matthew J., Draelos, Zoe D., DuBois, Janet, Kircik, Leon H., Moore, Angela Y., Stein Gold, Linda, Alonso-Llamazares, Javier, Bukhalo, Michael, Bruce, Suzanne, Eads, Kimmie, Green, Lawrence J., Guenthner, Scott T., Ferris, Laura K., Forman, Seth B., Kempers, Steven E., Lain, Edward, Lynde, Charles W., Pariser, David M., Toth, Darryl P., Yamauchi, Paul S., Higham, Robert C., Krupa, David, Burnett, Patrick, Berk, David R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2023
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10157502/
https://www.ncbi.nlm.nih.gov/pubmed/37133856
http://dx.doi.org/10.1001/jamadermatol.2023.0846

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10157502/
https://www.ncbi.nlm.nih.gov/pubmed/37133856
http://dx.doi.org/10.1001/jamadermatol.2023.0846

Ejemplares similares